(An Autonomous Body Recognized by Ministry of Commerce & Industry, Government of India)
MacroGenics axes ADC drug after Phase II failure in prostate cancer
MacroGenics has halted the development of vobramitamab duocarmazine (vobra duo) after its Phase II TAMARACK trial failed to show strong enough results in metastatic castration-resistant prostate cancer (mCRPC). The study reported radiographic progression-free survival (rPFS) of 9.5 months for the 2.0mg/kg group and 10 months for the 2.7mg/kg group, leading the company to discontinue investment. Following the announcement, MacroGenics’ stock dropped 10%.
Despite vobra duo’s failure, the company remains optimistic about targeting B7-H3 and is advancing its alternative ADC, MGC026, currently in a Phase I trial for solid tumors. MacroGenics is also exploring other prostate cancer treatments, including lorigerlimab, a bispecific PD-1 × CTLA-4 antibody in Phase II trials.
With prostate cancer cases projected to rise by 3.1% across major markets by 2033, research into new therapies remains critical despite setbacks like vobra duo’s disappointing results.
21-03-2025